Authored by Karl Simpson
ERYTECH has announced that Vanessa Mailer will join its Board of Directors in replacement for Dr. Alain Munoz as representative of Idinvest. Vanessa Mailer is a partner with KLS Partners in Paris, a venture capital group focused on early stage investments in the orphan drug and rare diseases field. Prior to her appointment at KLS Partners, Vanessa has a very successful career with Ipsen where she was VP Strategic Planning and Senior Director Business Development Oncology.
ERYTECH is a French biotech company established in Lyon in 2004 which has a lead product in the haematology area. Graspa is being developed in the area of acute lymphoblastic leukaemia (ALL) for relapsing patients. Their most advanced programme is in Phase III and data of the trial is expected to be reported later in the year. A further study is being conducted in the indication of acute myeloid leukaemia (AML). The product is licensed to Orphan Europe (Recordati) in the European markets and with Teva in Israel.